These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

327 related items for PubMed ID: 32348084

  • 1. Tofacitinib for the treatment of psoriasis and psoriatic arthritis.
    Ighani A, Georgakopoulos JR, Yeung J.
    G Ital Dermatol Venereol; 2020 Aug; 155(4):400-410. PubMed ID: 32348084
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Tofacitinib for the treatment of psoriasis and psoriatic arthritis.
    Berekmeri A, Mahmood F, Wittmann M, Helliwell P.
    Expert Rev Clin Immunol; 2018 Sep; 14(9):719-730. PubMed ID: 30118353
    [Abstract] [Full Text] [Related]

  • 4. Disease-specific composite measures for psoriatic arthritis are highly responsive to a Janus kinase inhibitor treatment that targets multiple domains of disease.
    Helliwell P, Coates LC, FitzGerald O, Nash P, Soriano ER, Elaine Husni M, Hsu MA, Kanik KS, Hendrikx T, Wu J, Kudlacz E.
    Arthritis Res Ther; 2018 Oct 29; 20(1):242. PubMed ID: 30373651
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Tofacitinib or adalimumab versus placebo: patient-reported outcomes from OPAL Broaden-a phase III study of active psoriatic arthritis in patients with an inadequate response to conventional synthetic disease-modifying antirheumatic drugs.
    Strand V, de Vlam K, Covarrubias-Cobos JA, Mease PJ, Gladman DD, Graham D, Wang C, Cappelleri JC, Hendrikx T, Hsu MA.
    RMD Open; 2019 Oct 29; 5(1):e000806. PubMed ID: 30713721
    [Abstract] [Full Text] [Related]

  • 10. Tofacitinib in psoriatic arthritis.
    Wang TS, Tsai TF.
    Immunotherapy; 2017 Nov 29; 9(14):1153-1163. PubMed ID: 28967798
    [Abstract] [Full Text] [Related]

  • 11. Tofacitinib: A Review in Psoriatic Arthritis.
    Paik J, Deeks ED.
    Drugs; 2019 Apr 29; 79(6):655-663. PubMed ID: 30895473
    [Abstract] [Full Text] [Related]

  • 12. Tofacitinib for Psoriatic Arthritis in Patients with an Inadequate Response to TNF Inhibitors.
    Gladman D, Rigby W, Azevedo VF, Behrens F, Blanco R, Kaszuba A, Kudlacz E, Wang C, Menon S, Hendrikx T, Kanik KS.
    N Engl J Med; 2017 Oct 19; 377(16):1525-1536. PubMed ID: 29045207
    [Abstract] [Full Text] [Related]

  • 13. Changes in Lipid Levels and Incidence of Cardiovascular Events Following Tofacitinib Treatment in Patients With Psoriatic Arthritis: A Pooled Analysis Across Phase III and Long-Term Extension Studies.
    Gladman DD, Charles-Schoeman C, McInnes IB, Veale DJ, Thiers B, Nurmohamed M, Graham D, Wang C, Jones T, Wolk R, DeMasi R.
    Arthritis Care Res (Hoboken); 2019 Oct 19; 71(10):1387-1395. PubMed ID: 31112005
    [Abstract] [Full Text] [Related]

  • 14. Efficacy and safety of Janus kinase inhibitors in patients with psoriasis and psoriatic arthritis: a systematic review and meta-analysis.
    Yang F, Lu C, Wang Y, Liu H, Leng X, Zeng X.
    Clin Rheumatol; 2023 Jun 19; 42(6):1593-1605. PubMed ID: 36763226
    [Abstract] [Full Text] [Related]

  • 15. Re-establishment of efficacy of tofacitinib, an oral JAK inhibitor, after temporary discontinuation in patients with rheumatoid arthritis.
    Kaine J, Tesser J, Takiya L, DeMasi R, Wang L, Snyder M, Soma K, Fan H, Bandi V, Wollenhaupt J.
    Clin Rheumatol; 2020 Jul 19; 39(7):2127-2137. PubMed ID: 32048083
    [Abstract] [Full Text] [Related]

  • 16. Adverse drug events associated with 5mg versus 10mg Tofacitinib (Janus kinase inhibitor) twice daily for the treatment of autoimmune diseases: A systematic review and meta-analysis of randomized controlled trials.
    Huang F, Luo ZC.
    Clin Rheumatol; 2019 Feb 19; 38(2):523-534. PubMed ID: 30242639
    [Abstract] [Full Text] [Related]

  • 17. Benefit-risk profile of tofacitinib in patients with moderate-to-severe chronic plaque psoriasis: pooled analysis across six clinical trials.
    Strober BE, Gottlieb AB, van de Kerkhof PCM, Puig L, Bachelez H, Chouela E, Imafuku S, Thaçi D, Tan H, Valdez H, Gupta P, Kaur M, Frajzyngier V, Wolk R.
    Br J Dermatol; 2019 Jan 19; 180(1):67-75. PubMed ID: 30188571
    [Abstract] [Full Text] [Related]

  • 18. Tofacitinib, an oral Janus kinase inhibitor, for the treatment of chronic plaque psoriasis: Long-term efficacy and safety results from 2 randomized phase-III studies and 1 open-label long-term extension study.
    Papp KA, Krueger JG, Feldman SR, Langley RG, Thaci D, Torii H, Tyring S, Wolk R, Gardner A, Mebus C, Tan H, Luo Y, Gupta P, Mallbris L, Tatulych S.
    J Am Acad Dermatol; 2016 May 19; 74(5):841-50. PubMed ID: 26899199
    [Abstract] [Full Text] [Related]

  • 19. New JAK inhibitors for the treatment of psoriasis and psoriatic arthritis.
    D'Urso DF, Chiricozzi A, Pirro F, Calabrese L, Caldarola G, Fossati B, De Simone C, Peris K.
    G Ital Dermatol Venereol; 2020 Aug 19; 155(4):411-420. PubMed ID: 32545945
    [Abstract] [Full Text] [Related]

  • 20. Efficacy and safety of tofacitinib monotherapy, tofacitinib with methotrexate, and adalimumab with methotrexate in patients with rheumatoid arthritis (ORAL Strategy): a phase 3b/4, double-blind, head-to-head, randomised controlled trial.
    Fleischmann R, Mysler E, Hall S, Kivitz AJ, Moots RJ, Luo Z, DeMasi R, Soma K, Zhang R, Takiya L, Tatulych S, Mojcik C, Krishnaswami S, Menon S, Smolen JS, ORAL Strategy investigators.
    Lancet; 2017 Jul 29; 390(10093):457-468. PubMed ID: 28629665
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 17.